Adherex Technologies Inc.
TSX : AHX
AMEX : ADH

Adherex Technologies Inc.

March 28, 2006 17:05 ET

Adherex Receives Regulatory Clearance For Phase II Weekly Dosing Schedule

RESEARCH TRIANGLE PARK, NORTH CAROLINA--(CCNMatthews - March 28, 2006) - Adherex Technologies Inc. (TSX:AHX)(AMEX:ADH), a biopharmaceutical company with a broad portfolio of oncology products under development, today announced that the Company has received regulatory clearance from Health Canada to convert the dosing schedule of its Phase II study of single agent ADH-1 to once every week from once every three weeks. Adherex is also adding clinical trial sites in the U.S. The trial is being performed at six centers in Canada.

"Based on our experience from our North American and European centers, this more dose dense, weekly dosing schedule of ADH-1 has been well tolerated and is preferable from a pharmacology standpoint," said William P. Peters, M.D., Ph.D., Chairman and CEO of Adherex.

This Phase II single-agent trial is designed to evaluate the anti-tumor activity and tolerability of repeated doses of ADH-1 in patients with lung, esophageal, adrenocortical, renal and hepatocellular cancers whose tumors express the molecular target N-cadherin. The trial is now expected to enroll up to an aggregate of 100 patients. The Company expects the trial to complete in the second half of 2006.

About Adherex Technologies

Adherex Technologies Inc. is a biopharmaceutical company dedicated to the discovery and development of novel cancer therapeutics. We aim to be a leader in developing innovative treatments that address important unmet medical needs in cancer. We currently have multiple products in the clinical stage of development, including ADH-1 (Exherin™), eniluracil and sodium thiosulfate (STS). ADH-1, our lead biotechnology compound, selectively targets N-cadherin, a protein present on certain tumor cells and established blood vessels that feed solid tumors. Eniluracil, an oral dihydropyrimidine dehydrogenase (DPD) inhibitor, was previously under development by GlaxoSmithKline for oncology indications. STS, a drug from our specialty pharmaceuticals pipeline, protects against the disabling hearing loss that can often result from treatment with platinum-based chemotherapy drugs. With a diversified portfolio of unique preclinical and clinical-stage cancer compounds and a management team with expertise in identifying, developing and commercializing novel cancer therapeutics, Adherex is emerging as a pioneering oncology company. For more information, please visit our website at www.adherex.com.

This press release contains forward-looking statements that involve significant risks and uncertainties. The actual results, performance or achievements of the Company might differ materially from the results, performance or achievements of the Company expressed or implied by such forward-looking statements. Such forward-looking statements include, without limitation, those regarding the development plans of the Company and the expected timing and results of such development. We can provide no assurance that such development will proceed as currently anticipated or that the expected timing or results of such development will be realized. We are subject to various risks, including our reliance on collaborative partners, the uncertainties of clinical trials, drug development and regulatory review, other risks inherent in the biopharmaceutical industry, the early stage of our product candidates, our need for additional capital to fund our operations, and our history of losses. For a more detailed discussion of related risk factors, please refer to our public filings available at www.sedar.com and www.sec.gov.

Contact Information

  • Adherex Technologies Inc.
    Melissa Matson
    Director, Corporate Communications
    (919) 484-8484
    matsonm@adherex.com